The Australian pharmaceutical market offers opportunities for manufacturers despite challenges.
Investors are lining up for the biosimilars market as patents reach expiration and regulatory pathways are defined.
The authors take a look at some of the recent developments in the German pharmaceutical market.
Data analytic strategies can help companies capitalize on personalized medicine.